Low‐dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD‐FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Low‐dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD‐FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience

Published:2019-03-12 Issue:2 Volume:37 Page:185-192
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Herishanu Yair¹²^ORCID,Tadmor Tamar³^ORCID,Braester Andrei⁴,Bairey Osnat²⁵,Aviv Ariel⁶,Rahimi‐Levene Naomi⁷,Fineman Riva⁸,Levi Itai⁹,Yuklea Mona¹⁰,Ruchlemer Rosa¹¹,Shvidel Lev¹²^ORCID,Polliack Aaron¹³

Affiliation:

1. Department of HematologyTel‐Aviv Sourasky Medical Center Tel‐Aviv Israel

2. Sackler Faculty of MedicineTel‐Aviv University Tel‐Aviv Israel

3. Hematology UnitBnai‐Zion Medical Center Haifa Israel

4. Department of HematologyGalilee Medical Center and Faculty of Medicine in Galilee Nahariya Israel

5. Department of HematologyRabin Medical Center Petah Tikva Israel

6. Department of HematologyEmek Medical Center Afula Israel

7. Department of HematologyAssaf Harofe Medical Center, Zerifin Israel

8. Department of HematologyRambam Medical Center Haifa Israel

9. Department of HematologySoroka Medical Center, Beer Sheba and Ben‐Gurion University, Beer Sheba Israel

10. Department of HematologySapir Medical Center Kfar Saba Israel

11. Department of HematologyShaare Zedek Medical Center Jerusalem Israel

12. Department of HematologyKaplan Medical Center Rehovot Israel

13. Department of HematologyHadassah University Hospital and Hebrew University Medical School Jerusalem Israel

Funder

Roche pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2580

Reference31 articles.

1. Chronic Lymphocytic Leukemia

2. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

3. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

4. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

5. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. H1N1 influenza virus dose dependent induction of dysregulated innate immune responses and STAT1/3 activation are associated with pulmonary immunopathological damage;Virulence;2022-09-09

2. Standard-Dose Rituximab as Effective Therapy for Treating Malignancy-Related Hemophagocytic Lymphohistiocytosis in the Eldery: A Case Report;Case Reports in Oncology;2021-07-05

3. Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies;Pathology and Oncology Research;2021-04-27

4. Low‐dose fludarabine and cyclophosphamide combined with rituximab in the first‐line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long‐term results of project Q‐lite by the Czech CLL Study Group;British Journal of Haematology;2021-02-22

5. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?;International Journal of Hematology;2020-04-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3